The FDA approves expanded access to daraxonrasib, the first RAS-targeting inhibitor for pancreatic cancer, which has shown promise in extending survival for metastatic patients in clinical trials.
The FDA has granted expanded access to Revolution Medicines’ targeted pancreatic cancer drug daraxonrasib, opening a pathway for more patients to receive a therapy that has shown promising results in clinical trials.
The U.S. FDA approves expanded access to daraxonrasib, a breakthrough targeted therapy for previously treated metastatic pancreatic ductal adenocarcinoma, offering new hope for patients with one of the deadliest cancers.
The US FDA approves expanded access to daraxonrasib, an innovative pancreatic cancer drug, offering new hope for patients facing one of the deadliest forms of cancer.
A US federal appeals court rules to temporarily halt FDA rules allowing mail-order access to the abortion drug mifepristone, significantly impacting reproductive healthcare access nationwide.
A US federal appeals court issued a temporary order blocking the FDA’s rule allowing women to obtain the abortion drug mifepristone by mail, a ruling that will impact drug accessibility nationwide.
The FDA approves an expanded access program for daraxonrasib, an innovative pancreatic cancer drug that showed promising results in clinical trials, offering new hope for patients with one of the most challenging cancers.
The U.S. FDA approves expanded early access for the experimental pancreatic cancer drug daraxonrasib, offering new hope for late-stage patients.
The US FDA has announced plans to introduce AI and real-time data technology to accelerate drug clinical trial approvals, marking a fundamental shift in drug development regulatory processes.
The FDA has approved Regeneron’s Otarmeni, the world’s first dual AAV vector-based gene therapy for severe-to-profound sensorineural hearing loss caused by OTOF gene mutations, with 80% of patients showing hearing improvement in clinical trials.